医学
内科学
危险系数
福尔菲里
结直肠癌
中性粒细胞与淋巴细胞比率
贝伐单抗
单变量分析
胃肠病学
多元分析
肿瘤科
比例危险模型
淋巴细胞
癌症
置信区间
伊立替康
化疗
作者
Emanuela Dell’Aquila,Chiara Cremolini,Tea Zeppola,Sara Lonardi,Francesca Bergamo,Gianluca Masi,Marco Stellato,Federica Marmorino,Marta Schirripa,Federica Urbano,M. Ronzoni,Giovanni Tomasello,Alberto Zaniboni,Patrizia Racca,Angela Buonadonna,Giacomo Allegrini,Elena Fea,Samantha Di Donato,S. Chiara,Giuseppe Tonini
标识
DOI:10.1093/annonc/mdy004
摘要
Neutrophil/lymphocyte ratio (NLR), defined as absolute neutrophils count divided by absolute lymphocytes count, has been reported as poor prognostic factor in several neoplastic diseases but only a few data are available about unresectable metastatic colorectal cancer (mCRC) patients (pts). The aim of our study was to evaluate the prognostic and predictive role of NLR in the TRIBE trial.Pts enrolled in TRIBE trial were included. TRIBE is a multicentre phase III trial randomizing unresectable and previously untreated mCRC pts to receive FOLFOXIRI or FOLFIRI plus bevacizumab. A cut-off value of 3 was adopted to discriminate pts with low (NLR < 3) versus high (NLR ≥ 3) NLR, as primary analysis. As secondary analysis, NLR was treated as an ordinal variable with three levels based on terciles distribution.NLR at baseline was available for 413 patients. After multiple imputation at univariate analysis, patients with high NLR had significantly shorter progression-free survival (PFS) [hazard ratio (HR) 1.27 (95% CI 1.05-1.55), P = 0.017] and overall survival (OS) [HR 1.56 (95% CI 1.25-1.95), P < 0.001] than patients with low NLR. In the multivariable model, NLR retained a significant association with OS [HR 1.44 (95% CI 1.14-1.82), P = 0.014] but not with PFS [HR 1.18 (95% CI 0.95-1.46), P = 0.375]. No interaction effect between treatment arm and NLR was evident in terms of PFS (P for interaction = 0.536) or OS (P for interaction = 0.831). Patients with low [HR 0.84 (95% CI 0.64-1.08)] and high [HR 0.73 (95% CI 0.54-0.97)] NLR achieved similar PFS benefit from the triplet and consistent results were obtained in terms of OS [HR 0.83 (95% CI 0.62-1.12) for low NLR; HR 0.82 (95% CI 0.59-1.12) for high NLR].This study confirmed the prognostic role of NLR in mCRC pts treated with bevacizumab plus chemotherapy in the first line, showing the worse prognosis of pts with high NLR. The advantage of the triplet is independent of NLR at baseline.
科研通智能强力驱动
Strongly Powered by AbleSci AI